Status:
ACTIVE_NOT_RECRUITING
A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Researchers have designed a new study medicine called MK-4646 as a new way to treat human immunodeficiency virus (HIV). Rifabutin is a medication used to treat tuberculosis (TB). Researchers want to ...
Eligibility Criteria
Inclusion
- The main inclusion criteria include but are not limited to:
- Is in good health
- Has a body-mass index (BMI) between 18 and 32 kg/m2
- The main exclusion criteria include but are not limited to:
- Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- Has a history of cancer (malignancy)
Exclusion
Key Trial Info
Start Date :
October 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 27 2025
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT07199452
Start Date
October 28 2025
End Date
December 27 2025
Last Update
November 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fortea CRU Madison ( Site 0001)
Madison, Wisconsin, United States, 53704